Business
Initiation of a Phase I clinical trial with AGS-v
Initiation of a Phase I clinical trial with AGS-v.
About this update from Hvivo Plc
[{"type":"text","content":"\n \nRNS Number : 4741X hVIVO plc 21 February 2017 \n\nFor immediate release 16:25: 21 February 2017\n \n \nHVIVO PLC\n(\"hVIVO\" or the \"Company\")\n \nhVIVO notes the initiation of a Phase I clinical trial with AGS-v, a mosquito-borne disease vaccine candidate\n \nVaccine could protect against diseases such as Zika and Malaria \n \nhVIVO's joint venture investment with SEEK in a new company, Imutex, was formed to accelerate the development of this vaccine\n \n \nhVIVO plc (AIM: HVO), a specialty biopharma company with discovery and clinical testing capabilities, notes the announcement from the US National Institute of Health (NIH) that it has initiated a Phase I clinical trial of AGS-v, an investigational mosquito-borne disease vaccine. AGS-v is intended to provide broad protection against a range of mosquito-transmitted diseases, such as Zika, malaria, West Nile fever and dengue fever, and to hinder the ability of mosquitoes to transmit such infections. The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, is leading the trial, which will enrol up to 60 healthy adults ages 18-50 years, and is designed to test the safety of the investigational vaccine, as well as its ability to prompt an immune response in human subjects. \n \nIn 2016, hVIVO formed a joint venture with London-based SEEK Group (SEEK) in a new company, Imutex Limited (Imutex), to accelerate the development of SEEK's AGS-v vaccine and broad-spectrum influenza vaccine (BIV), FLU-v. Such vaccines are key public health priorities identified by the Centers for Disease Control and Prevention (CDC), the NIH, and other international health authorities. SEEK, through its parent company PepTcell Limited, has a clinical trial agreement with NIAID to conduct the Phase I study at the NIH Clinical Center in Bethesda, Maryland under the direction of Matthew J. Memoli, M.D., Director of the Clinical Studies Unit in NIAID's Laboratory of Infectious Diseases.\n \nUnlike other vaccines targeting specific mosquito-borne diseases, AGS-v is designed to trigger an immune response to mosquito saliva rather than a specific virus or parasite carried by mosquitoes. The test vaccine contains four synthetic proteins from mosquito salivary glands. The proteins are designed to induce antibodies in a vaccina...